Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome

Thrombosis Research

Volumn 153, Issue , 2017, Pages 90-94

  Iwaniec, Teresa ^a   Kaczor, Marcin P ^a   Celińska Löwenhoff, Magdalena ^a   Polański, Stanisław ^a   Musiał, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anti D1 2GPI IgG antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Thromboembolic risk

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 85016294465     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.02.019     Document Type: Article

References (34)

1. [1] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4 (2006), 295–306.
2. [2] De Laat, B., Derksen, R.H., De Groot, P.G., Beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin. Immunol. 112 (2004), 161–168.
3. [3] McNeil, H.P., Simpson, R.J., Chesterman, C.N., Kirllis, S.A., Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 4120–4124.
4. [4] Iverson, G.M., Reddel, S., Victoria, E.J., Cockerill, K.A., Wang, Y.X., Marti-Renom, M.A., et al. Use of single point mutations in domain I of beta2-glycoprotein I to determine fine antigenic specificity of antiphospholipides autoantibodies. J. Immunol. 169 (2002), 7097–7103.
5. [5] De Laat, B., van Berkel, M., Urbanus, R.T., Siregar, B., de Groot, P.G., Gebbink, M.F., et al. Immune response against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 63 (2011), 3960–3968.
6. [6] Galli, M., Luciani, D., Bertollini, G., Barbui, T., Lupus anticoagulant are stronger risk factors for thrombosis than aticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003), 1827–1832.
7. [7] De Laat, B., Derksen, R.H., Urbanus, R.T., Roest, M., De Groot, P.G., Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004), 3598–3602.
8. [8] Pengo, V., Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., IIliceto, S., Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93 (2005), 1147–1152.
9. [9] De Laat, B., De Groot, P.G., Autoantibodies directed against domain I of beta2-glycoprotein I. Curr. Rheumatol. Rep. 13 (2011), 70–76.
10. [10] De Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E., et al. The association between circulating antibodies against domain Iof beta 2-glycoprotein I and thrombosis; an international multicenter study. J. Thromb. Haemost. 7 (2009), 1767–1773.
11. [11] De Laat, B., Derksen, R.H., Urbanus, R.T., De Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545.
12. [12] Banzato, A., Pozzi, N., Frasson, R., De Filippis, V., Ruffatti, A., Bison, E., et al. Antibodies to domain I of β2 glycoprotein I are in close relation to patients risk categories in atiphospholipd syndrome (APS). Thromb. Res. 128 (2011), 583–586.
13. [13] Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., et al. Antiphospholpid syndrome: antibodies to domain 1 of β2-glycoprotein I correctly classify patients risk. J. Thromb. Haemost. 13 (2015), 782–787.
14. [14] Devreese, K., Standardization of antiphospholipid antibody assays. Where do we stand?. Lupus 21 (2012), 718–721.
15. [15] Pelkmans, L., Kelchtermans, H., de Groot, P.G., Zuily, S., Regnault, V., Wahl, D., et al. Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS ONE, 8(8), 2013, e71402, 10.1371/journal.pone.0071402.
16. [16] Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982), 1271–1277.
17. [17] Devreese, K.M.J., Pierangeli, S.S., De Laat, B., Tripodi, A., Atsumi, T., Ortel, T.L., Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 12 (2014), 792–795.
18. [18] Linnet, K., Nonparametric estimation of reference intervals by simple and bootstrap-based procedures. Clin. Chem. 46 (2000), 867–869.
19. [19] Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7 (2009), 1737–1740.
20. [20] Moore, G.W., Recent guidelines and recommendation for laboratory detection of lupus anticoagulants [in focus article]. Semin. Thromb. Hemost. 40:2 (2014), 163–171.
21. [21] Zhang, S., Wu, Z., Chen, S., Li, J., Wen, X., Li, L., et al. Evaluation of the diagnostics potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci. Rep., 6, 2016, 23839, 10.1038/srep23839.
22. [22] Meneghel, L., Ruffatti, A., Gavasso, S., Tonello, M., Mattia, E., Spiezia, L., et al. Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin. Chim. Acta 446 (2015), 201–205.
23. [23] De Craemer, A.S., Musial, J., Devreese, K.M.J., Role of anti-domain 1-β2glycoprotein I antibodies and risk stratification of antiphospholipid syndrome. J. Thromb. Haemost. 14:9 (2016 Sep), 1779–1787, 10.1111/jth.13389.
24. [24] Zhang, S., Wu, Z., Zhang, F., Li, Y., Role of anti-domain 1-B2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: comment. J. Thromb. Haemost. 14 (2016), 2076–2078.
25. [25] Mondejar, R., Gonzalez-Rodriguez, C., Toyos-Saenz de Miera FJ, Melguizo-Madrid E, Zohoury N, Mahler M, et al. role of antiphospholid score and anti-β2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin. Chim. Acta 431 (2014), 174–178.
26. [26] Iwaniec, T., Kaczor, M.P., Celińska-Löwenhoff, M., Polański, S., Musiał, J., Clinical utility of automated chemiluminescent antiphospholipid antibody assay. Thromb. Res. 136:5 (2015 Nov), 1033–1039.
27. [27] Iwaniec, T., Kaczor, M.P., Celińska-Löwenhoff, M., Polański, S., Musiał, J., Identification of patients with triple antiphospholipid antibody positivity is platform and method independent. Pol. Arch. Med. Wewn. 126:1–2 (2016), 19–24.
28. [28] Devreese, K.M., Pocet, A., Lindhoff-Last, E., Musial, J., de Moerloose, P., Fontana, P., A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. J. Thromb. Haemost., 2016, 10.1111/jth.13560 (E-pub ahead of print).
29. [29] Mondejar, R., Gonzalez-Rodriguez, C., Toyos-Saenz de Miera, F.J., Melguizo-Madrid, E., Zohoury, N., Mahler, M., et al. Role of antiphospholipid score and anti-β2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin. Chim. Acta 431 (2014), 174–178.
30. [30] Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 8 (2010), 237–242.
31. [31] Otomo, K., Atsumi, T., Amengual, O., Fujieda, Y., Kato, M., Oku, K., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 64 (2012), 504–512.
32. [32] Lim, W., Thrombotic risk in the antiphospholipid syndrome. Semin. Thromb. Hemost. 40 (2014), 741–746.
33. [33] Mahler, M., Norman, G.L., Meroni, P.L., Khamashta, M., Autoantibodies to domain 1 of beta 2 glycoprotein I: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun. Rev. 12 (2012), 313–317.
34. [34] De Laat, B.H., Derksen, R.H.W.M., Urbanus, R.T., Roest, M., de Groot, P.G., β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004), 3598–3602.